Why has there been no further reporting on this trial?
According to the announcement, the 2nd and 3rd patients of the first cohort were to receive their first dose "soon". And then the Safety Review Committee would review the 4 week safety data to enable the trial to move onto the next higher dose.
Unless there was an issue with getting the patients in for their 4 week follow up, I expect that the Cohort 1 safety review should have been completed before Xmas and the trial would be into Cohort 2 by now.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.005(0.42%) |
Mkt cap ! $691.1M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.19 | $410.5K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15611 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |